Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGTINASDAQ:AXNXNASDAQ:IMCRNASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTIAgiliti$10.06$5.07▼$18.61$1.37B1.91.78 million shs26.51 million shsAXNXAxonics$70.98$70.61$67.01▼$71.05$3.63B0.82417,472 shsN/AIMCRImmunocore$31.70-2.0%$31.58$23.15▼$41.54$1.59B0.83359,871 shs444,801 shsNUVLNuvalent$75.53-0.7%$73.82$55.54▼$113.51$5.42B1.34493,725 shs360,890 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTIAgiliti0.00%0.00%0.00%0.00%0.00%AXNXAxonics0.00%0.00%0.00%0.00%+5.14%IMCRImmunocore0.00%-11.03%-2.13%+6.34%-11.80%NUVLNuvalent0.00%-3.05%-0.46%-3.12%-3.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTIAgilitiN/AN/AN/AN/AN/AN/AN/AN/AAXNXAxonicsN/AN/AN/AN/AN/AN/AN/AN/AIMCRImmunocore2.271 of 5 stars4.30.00.00.02.12.50.0NUVLNuvalent2.1941 of 5 stars3.52.00.00.01.53.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTIAgiliti 0.00N/AN/AN/AAXNXAxonics 2.00HoldN/AN/AIMCRImmunocore 2.55Moderate Buy$58.8985.77% UpsideNUVLNuvalent 2.90Moderate Buy$115.5052.92% UpsideCurrent Analyst Ratings BreakdownLatest AGTI, NUVL, AXNX, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTIAgiliti$1.17B0.00N/A5.76$6.98 per share0.00AXNXAxonics$366.38M9.90$0.13 per share561.96$12.59 per share5.64IMCRImmunocore$310.20M5.13N/AN/A$7.20 per share4.40NUVLNuvalentN/AN/AN/AN/A$14.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTIAgiliti-$19.42M-$0.14N/A0.00N/A-1.65%6.47%2.53%N/AAXNXAxonics-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/AIMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)NUVLNuvalent-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)Latest AGTI, NUVL, AXNX, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTIAgilitiN/AN/AN/AN/AN/AAXNXAxonicsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTIAgiliti1.131.721.34AXNXAxonicsN/A8.166.40IMCRImmunocore1.036.366.31NUVLNuvalentN/A14.4814.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTIAgiliti99.12%AXNXAxonics99.48%IMCRImmunocore84.50%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipAGTIAgiliti4.16%AXNXAxonics1.85%IMCRImmunocore10.40%NUVLNuvalent10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTIAgiliti5,800136.08 million130.42 millionOptionableAXNXAxonics61051.11 million50.16 millionOptionableIMCRImmunocore32050.23 million45.01 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableAGTI, NUVL, AXNX, and IMCR HeadlinesRecent News About These CompaniesNuvalent Appoints Christy Oliger to Board of DirectorsJune 18 at 4:30 PM | prnewswire.comGAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL)June 18 at 3:13 AM | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Receives $115.50 Consensus PT from BrokeragesJune 18 at 2:47 AM | americanbankingnews.comNuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stockJune 15, 2025 | investing.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 15, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 200 SharesJune 11, 2025 | insidertrades.comInsider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 200 Shares of StockJune 10, 2025 | marketbeat.comNuvalent Board Member Emily Conley ResignsJune 10, 2025 | tipranks.comCalifornia State Teachers Retirement System Purchases 5,109 Shares of Nuvalent, Inc. (NASDAQ:NUVL)June 6, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Nuvalent, Inc. (NASDAQ:NUVL)June 2, 2025 | marketbeat.comNuvalent, Inc. Reports Q1 2025 Financial ResultsMay 31, 2025 | tipranks.comNuvalent (NASDAQ:NUVL) Stock Price Up 6.2% - Time to Buy?May 30, 2025 | marketbeat.comSquarepoint Ops LLC Reduces Position in Nuvalent, Inc. (NASDAQ:NUVL)May 29, 2025 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Polar Asset Management Partners Inc.May 28, 2025 | marketbeat.comVoloridge Investment Management LLC Has $13.37 Million Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 26, 2025 | marketbeat.comTwo Sigma Advisers LP Decreases Stake in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comTwo Sigma Investments LP Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL)May 25, 2025 | marketbeat.comNuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal yearMay 24, 2025 | investing.comTwinbeech Capital LP Invests $2.32 Million in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comDeutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)May 24, 2025 | marketbeat.comMan Group plc Purchases 41,447 Shares of Nuvalent, Inc. (NASDAQ:NUVL)May 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTI, NUVL, AXNX, and IMCR Company DescriptionsAgiliti NYSE:AGTIAgiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.Axonics NASDAQ:AXNXAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Immunocore NASDAQ:IMCR$31.70 -0.66 (-2.04%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$31.72 +0.02 (+0.06%) As of 06/18/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Nuvalent NASDAQ:NUVL$75.53 -0.53 (-0.70%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$75.55 +0.02 (+0.03%) As of 06/18/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
